Spirea, a biotech company spun out from the University of Cambridge, is committed to delivering the next generation of antibody drug conjugate (ADC) therapeutics to revolutionise cancer treatment and improve the lives of patients.
Location: United Kingdom, England, Knaresborough
Employees: 11-50
Total raised: $5.91M
Founded date: 2017
Investors 6
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| - | Angel CoFu... | acfinvesto... |
| - | Start Codo... | startcodon... |
| - | Syndicate ... | syndicater... |
| 27.06.2022 | Cambridge ... | cambridgea... |
| - | Parkwalk A... | parkwalkad... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.06.2022 | - | $2.91M | - |
| 14.06.2022 | - | $3M | - |
Mentions in press and media 10
| Date | Title | Description |
| 07.02.2023 | #21toWatch announces shortlist of next generation of Cambridge game-changers set for future success | cofinitive have announced the shortlist for #21toWatch 2023 which this year contains an eclectic mix of industries – biotech, cleantech, agritech, construction, automotive, deep learning, marine, life sciences, AI – all sharing the same mis... |
| 15.06.2022 | Sequoia Capital published 3 new survival guides for startups | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Free cash flow. Reduce risk. Go FOF yourself. Paid Content How Northrop Grumman uses ESG as an en... |
| 14.06.2022 | Spirea, a startup developing antibody drug conjugates in cancer, nabs $3 million | Cambridge-based biotech company Spirea has raised $3 million to advance a new generation of antibody drug conjugate (ADC) therapeutics. The round was co-led by Jonathan Milner and Cambridge Enterprise, with backing from R42 Group, ACF Inves... |
| 14.06.2022 | Spirea raises £2.4M ($3M) to develop antibody drug conjugates in cancer | Cambridge - Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has announced that it has secured funding of £2.4 million with investments from high-profile UK and US invest... |
| 14.06.2022 | Spirea Raises £2.4M in Funding | Spirea Limited, a Cambridge, England, UK-based company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, raised £2.4m in funding. The round was co-led by Jonathan Milner and Cambridge Enterprise with partici... |
| 14.06.2022 | Spirea Raises £2.4M ($3M) to Develop Antibody Drug Conjugates in Cancer | - |
| 07.12.2020 | Spirea secures further financing to develop the next generation of antibody drug conjugate therapeutics | Spirea Limited, a spin-out from the University of Cambridge, which was founded to deliver the next generation of antibody drug conjugate (ADC) cancer therapeutics, has today announced that it has secured financing from lead o2h Ventures and... |
| 07.12.2020 | Spirea secures further financing to develop the next generation of antibody drug conjugate therapeutics | Spirea secures further financing to develop the next generation of antibody drug conjugate therapeutics 07-12-2020 Spirea Limited, a spin-out from the University of Cambridge, which was founded to deliver the next generation of antibody dru... |
| 23.06.2020 | Shooting stars unveiled in Start Codon’s first contingent | Cambridge UK healthcare accelerator Start Codon has revealed its first cohort of early stage businesses destined for life science stardom. Article by Tony Quested | Business Weekly The organisation aims to minimise risk and translate early ... |
| - | Spirea, a startup developing antibody drug conjugates in cancer, nabs $3 million | Cambridge-based biotech company Spirea has raised $3 million to advance a new generation of antibody drug conjugate (ADC) therapeutics. The round was co-led by Jonathan Milner and Cambridge Enterprise, with backing from R42 Group, ACF Inves... |